Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
Roberta Forlano, Mathuri Sivakumar, Benjamin H. Mullish, Pinelopi Manousou
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.
Topics & Concepts
Fatty liverDiseaseMicrobiomeMedicinePathogenesisLiver diseasePopulationAlcoholic liver diseaseBioinformaticsIntensive care medicineImmunologyGastroenterologyBiologyInternal medicineCirrhosisEnvironmental healthLiver Disease Diagnosis and TreatmentGut microbiota and healthDiet and metabolism studies